Merck & Co.
NYSE:MRKPharmaRahway, NJ, United States · Est. 1891 · 69,000 employees
Global healthcare company delivering innovative health solutions.
63
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
91
Indications↗
Distinct diseases across all programs
2,780
Clinical Trials↗
All sponsored trials (all statuses)
18
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
63 drugs in development
Phase 323
Phase 230
Phase 119
Preclinical24
By Therapeutic Area
top 6
Oncology
3952%
Infectious Disease
79%
Metabolic & Endocrine
57%
Immunology
57%
Cardiovascular
23%
Respiratory
11%
R&D Momentum
100/100
Pipeline Velocity
86/100
Trial Completion Rate
83/100
Pipeline Concentration
33/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Active in Cardiovascular but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 10, 2026
Recruiting
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Oct 10, 2026
Recruiting
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
Oct 10, 2026
Recruiting
A Phase 1, Open-Label, Drug Interaction Study to Assess the Effects of Probenecid, a Probe UGT Enzyme Inhibitor, on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
Oct 10, 2026
Recruiting
Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of MK-2010 in Combination With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Advanced Solid Tumors
Oct 10, 2026
Recruiting
A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Oct 10, 2026
Recruiting
A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Oct 10, 2026
Recruiting
A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer
Oct 10, 2026
Completed
A Clinical Study to Evaluate the Relative Bioavailability of MK-1403 Formulations Administered to Healthy Adult Participants
Oct 10, 2026
Recruiting
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
Oct 9, 2026
Recruiting
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
Oct 9, 2026
Completed
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)
Details
Company Info
Company Overview
$290.0B
Mkt Cap
$60.1B
Revenue
$7.4B
Cash
CEORobert Davis
Founded1891
Employees69,000
HQRahway, NJ, United States
ExchangeNYSE:MRK
Websitemerck.com
LinkedInCompany Page
Therapeutic Focus
OncologyInfectious DiseaseMetabolic & EndocrineHematologyOtherImmunologyGastroenterologyCardiovascularPsychiatryNephrologyOphthalmologyNeurologyMusculoskeletalRespiratoryRare Disease
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(2 drugs)
—
—
—
2
—
Cardiovascular(2 drugs)
Hematology(1 drug)
—
—
1
—
—
Hematology(1 drug)
Immunology(5 drugs)
—
—
1
4
—
Immunology(5 drugs)
Infectious Disease(7 drugs)
2
—
4
1
—
Infectious Disease(7 drugs)
Metabolic & Endocrine(5 drugs)
1
1
—
4
—
Metabolic & Endocrine(5 drugs)
Oncology(39 drugs)
20
13
20
11
—
Oncology(39 drugs)
Respiratory(1 drug)
—
—
—
1
—
Respiratory(1 drug)
Unknown / Other(15 drugs)
4
5
5
3
—
Unknown / Other(15 drugs)
Regulatory
Regulatory Timeline
20245 events
FDANov 25
Insulin — SEMGLEE
Application BLA761201
FDANov 1
Insulin — SOLIQUA 100/33
Application BLA208673
FDANov 1
Insulin — XULTOPHY 100/3.6
Application BLA208583
FDAAug 29
Insulin — TOUJEO SOLOSTAR, TOUJEO MAX SOLOSTAR
Application BLA206538
FDAAug 9
Insulin — REZVOGLAR
Application BLA761215
20259 events
FDAOct 14
Insulin — XULTOPHY 100/3.6
Application BLA208583
FDAJul 15
Insulin — KIRSTY
Application BLA761188
FDAJun 9
ENFLONSIA — ENFLONSIA
Application BLA761432 (BLA)
FDAMay 28
Insulin — SOLIQUA 100/33
Application BLA208673
FDAMay 28
Insulin — XULTOPHY 100/3.6
Application BLA208583
FDAMay 7
Insulin — HUMALOG KWIKPEN, HUMALOG PEN, HUMALOG TEMPO PEN, HUMALOG
Application BLA020563
FDAMay 7
Insulin — HUMALOG KWIKPEN
Application BLA205747
FDAMar 7
Insulin — MYXREDLIN
Application BLA208157
FDAFeb 14
Insulin — MERILOG, MERILOG SOLOSTAR
Application BLA761325
20266 events
FDASep 15
Insulin — GARZULYS
Application BLA761497
FDAJul 24
Insulin — GARZULYS
Application BLA761497
FDAMay 29
Insulin — AFREZZA
Application BLA022472
FDAApr 20
Islatravir — IDVYNSO
Application NDA216964
FDAMar 12
Insulin — SOLIQUA 100/33
Application BLA208673
FDAJan 23
Insulin — AFREZZA
Application BLA022472
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)